Technical Information Compound Name: Tirzepatide Peptide Classification: Dual GIP/GLP-1 Receptor Agonist Molecular Formula: CHNO Appearance: White to off-white lyophilized powder Solubility: Typically soluble in bacteriostatic water or suitable research-grade diluents Research Category: Metabolic and incretin-pathway research peptide Common Research Areas GIP and GLP-1 receptor signaling Glucose-homeostasis investigations Appetite and satiety-related research Adipose and metabolic-regulation studies Cardiometabolic and obesity-related research Endocrine and energy-balance pathway investigations For Laboratory and Research Use Only Not for human consumption or therapeutic use
While the standard recommendation is 0.8 grams per kilogram of body weight, patients on GLP-1 medications should aim higher: Target intake: 1.2-1.6 grams of protein per kilogram of body weight daily Distribution: 25-30 grams per meal, spread across 3-4 meals Priority sources: Complete proteins containing all essential amino acids (eggs, fish, poultry, dairy, or combined plant sources) For a 170-pound (77 kg) patient, this translates to approximately 92-123 grams of protein daily
A small needle is used to administer the glutathione solution intravenously, usually into a vein in the arm
Kidney supplements that need more research Research on vitamins, minerals, and herbal supplements intended to improve kidney health still needs to be completed, especially in CKD patients
Even when consumed in large quantities, the potential for toxicity is low because the body does not retain most B12 that is consumed
